Panasonic teams up with 7X Paralympic Champion Hannah Cockroft for Paris 2024 Paralympic Games
31.8.2023 18:31:00 EEST | Business Wire | Press release
Celebrating the countdown to the Paris 2024 Paralympic Games, Worldwide Olympic and Paralympic Partner Panasonic joins forces with the Team England wheelchair racing 7-time Paralympic Champion and 12-time World Champion, Hannah Cockroft to promote environmental sustainability on a global scale.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230831059501/en/
Hannah Cockroft (Photo: Business Wire)
Since its founding, Panasonic has been committed to making positive contributions to the world and society. It has set ambitious targets to create a positive impact on environmental sustainability under its Panasonic GREEN IMPACT initiative. Hannah will join Team Panasonic as an ambassador focused on sustainability and inclusivity while receiving support from the company on her journey to her fourth Paralympic Games.
After picking up wheelchair racing at a talent day at Loughborough University in October 2007, Hannah has blazed a trail straight to legend status. As one of the most successful para-athletes in recent times, Hannah is looking forward to continuing to inspire people all over the world to embrace the Paralympic movement and celebrate inclusion.
Besides her tremendous athletic achievements, Hannah was one of 50+ Tokyo Olympians and Paralympians from 35 different countries, who took part in the Athletes of the World campaign which challenged World Leaders about the urgent need for ambitious climate action.
She is additionally using her platform to make a difference in issues beyond the sports arena, such as working with federations to reduce the use of single-use plastics. Panasonic is looking forward to working together with her on similar projects and initiatives that epitomise Panasonic’s core values of Contribution to Society, Cooperation & Team Spirit, and Untiring Effort & Improvement.
Hannah Cockroft comments, “It is a privilege to have Panasonic supporting me as I head into the Paris 2024 Paralympic Games. The backing and promotion to a wider audience will help me retain my top performing athlete position and enable me in turn to champion the need for climate change action, and increased inclusivity on a wider scale.”
Panasonic Champions the Champions
Panasonic has supported the Olympic and Paralympic Movements and their Athletes for nearly four decades. Several world-class athletes have been part of its Team Panasonic extended family. These athletes are committed to breaking barriers, improving communities, and bringing awareness to important issues such as sustainability, diversity, and inclusivity, and Hannah is no exception.
Junichi Suzuki, Chairman and CEO of Panasonic Europe B.V. comments, “Hannah’s focus on societal change, including being a patron and ambassador for several charities that enable her to encourage others to get active, alongside her participation in the sustainability initiatives, embodies the spirit of Team Panasonic.
We are proud to welcome her to the Team Panasonic family and have her be part of our team to shine a light on global climate change initiatives and innovations that tackle the world’s most pressing environmental problems.”
For more information about Panasonic GREEN IMPACT vision visit: https://www.panasonic.com/uk/corporate/sustainability.html
For more information about Panasonic as a Worldwide Olympic and Paralympic Partner visit: Panasonic Official Olympic & Paralympic Website| Panasonic Holdings
About the Panasonic Group
Founded in 1918, and today a global leader in developing innovative technologies and solutions for wide-ranging applications in the consumer electronics, housing, automotive, industry, communications, and energy sectors worldwide, the Panasonic Group switched to an operating company system on April 1, 2022 with Panasonic Holdings Corporation serving as a holding company and eight companies positioned under its umbrella. The Group reported consolidated net sales of 8,378.9 billion yen (ca. 59.4 billion Euro) for the year ended March 31, 2023.
To learn more about the Panasonic Group, please visit: https://holdings.panasonic/global/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230831059501/en/
Contact information
Tanya Houston, Wildwood Plus, tanya.houston@wildwoodplus.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 14:30:00 EEST | Press release
Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom